JPMorgan Chase & Co. Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

JPMorgan Chase & Co. lowered its position in Autolus Therapeutics plc (NASDAQ:AUTL) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,071,533 shares of the company’s stock after selling 213,175 shares during the quarter. JPMorgan Chase & Co. owned about 0.40% of Autolus Therapeutics worth $2,518,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dumont & Blake Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $35,000. Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics in the fourth quarter worth approximately $47,000. Daiwa Securities Group Inc. increased its stake in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after acquiring an additional 8,479 shares during the last quarter. Avanza Fonder AB purchased a new stake in Autolus Therapeutics in the fourth quarter valued at $75,000. Finally, Handelsbanken Fonder AB lifted its stake in shares of Autolus Therapeutics by 30.9% in the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company’s stock valued at $172,000 after purchasing an additional 17,300 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.60 on Wednesday. The company’s 50-day simple moving average is $1.67 and its 200-day simple moving average is $2.51. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The stock has a market capitalization of $425.75 million, a PE ratio of -1.32 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. On average, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on AUTL shares. Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st. Truist Financial reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.